SAN DIEGO, Feb. 11, 2020 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that a clinical study conducted in Mexico using its Real Scientific Hemp Oil-X™ cannabidiol (CBD) oil has been completed and published in the EC Neurology (ECNE), an internationally peer-reviewed journal that publishes articles related to worldwide research in neuroscience.
"We are encouraged by the study's results and look forward to understanding more about CBD's potential effects as we continue to conduct research on this topic," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "There are many people who are already using our products to experience a variety of health and wellness benefits. We believe that with the added assurance of these results, there will be many other people who may take interest in our products."
"For many children, there are countless pharmaceutical drugs that either don't work for them or produce a variety of harmful side effects," said Dr. Carlos G. Aguirre-Velázquez, a globally recognized pediatric neurologist and lead researcher on the study. "We are optimistic that this study will be one of many that showcases the potential for hemp CBD oil to be safe and useful."
This is just one example of the Company's dedication to furthering innovative research within the cannabis industry. In 2019, Medical Marijuana, Inc. completed a one-year stability study in compliance with FDA/ICH guidelines on RSHO®-X and found that the product showed no change (less than 5%) in the CBD content, viscosity, package compatibility and complete microbial characteristics.
To read the full study, please click here.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its internal R&D and scientific team and its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Investor Relations Contact:
P. (858) 283-4016
SOURCE Medical Marijuana, Inc.